written on 05.06.2014
Tags:
,

Glaxo settles multi-state off-label marketing probe with $105M fine

TAGS: ,

GlaxoSmithKline's latest penalty for improper marketing practices may seem little more than a slap on the hand–except that it's coming at the worst possible time for the embattled British drugmaker. GSK agreed to pay $105 million to settle charges in California, New York, Texas and more than 40 other states that it illegally promoted its asthma drug Advair and antidepressants Wellbutrin and Paxil.

Latest Report